Literature DB >> 8972053

Cross-protection between Actinobacillus pleuropneumoniae biotypes-serotypes in pigs.

F Haesebrouk1, A Van de Kerkhof, P Dom, K Chiers, R Ducatelle.   

Abstract

Four groups of hysterectomy-derived and colostrum-deprived pigs were intranasally inoculated with an Actinobacillus pleuropneumoniae biotype 1-serotype 2 strain (producing RTX toxins ApxII and ApxIII. 6 pigs), an A. pleuropneumoniae biotype 1-serotype 10 strain (producing ApxI. 5 pigs), an A. pleuropneumoniae biotype 2-serotype 2 strain (producing ApxII, 5 pigs) or saline (controls, 7 pigs). All pigs were exposed to A. pleuropneumoniae biotype 1-serotype 2 endobronchial challenge. After challenge, severe clinical signs were observed in all control pigs, one pig immunized with the A. pleuropneumoniae biotype 1-serotype 10 strain and two pigs immunized with the A. pleuropneumoniae biotype 2-serotype 2 strain. These pigs died within 36 h after challenge and 20 to 50% of the lungs were macroscopically affected. In the other pigs, clinical signs were mild or absent and no or only small, focal lung lesions were observed when euthanized at 48 h after challenge. At the time challenge neutralizing antibodies against ApxI only. ApxII only and both ApxII and III were present in sera of pigs immunized with the A. pleuropneumoniae biotype 1-serotype 10 strain, the A. pleuropneumoniae biotype 2-serotype 2 strain and the A. pleuropneumoniae biotype 1-serotype 2 strain, respectively. These results indicate that immune mechanisms other than Apx neutralizing antibodies were involved in partial cross-protection of pigs immunized against A. pleuropneumoniae biotype 1-serotype 10 and challenged with the A. pleuropneumoniae biotype 1-serotype 2.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972053     DOI: 10.1016/s0378-1135(96)00075-2

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  7 in total

1.  Use of an Actinobacillus pleuropneumoniae multiple mutant as a vaccine that allows differentiation of vaccinated and infected animals.

Authors:  Alexander Maas; Ilse D Jacobsen; Jochen Meens; Gerald-F Gerlach
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Involvement of the Actinobacillus pleuropneumoniae ompW Gene in Confrontation of Environmental Pressure.

Authors:  Xiabing Chen; Zhiyong Shao; Lijun Wu; Bin He; Wenhai Yang; Jie Chen; Erguang Jin; Qi Huang; Liancheng Lei; Jiajia Xu; Haotian Li; Hui Zhang; Yun Wan; Wu Liu; Rui Zhou
Journal:  Front Vet Sci       Date:  2022-05-19

3.  Identification of Actinobacillus pleuropneumoniae genes important for survival during infection in its natural host.

Authors:  Brian J Sheehan; Janine T Bossé; Amanda J Beddek; Andrew N Rycroft; J Simon Kroll; Paul R Langford
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

4.  Adhesion protein ApfA of Actinobacillus pleuropneumoniae is required for pathogenesis and is a potential target for vaccine development.

Authors:  Yang Zhou; Lu Li; Zhaohui Chen; Hong Yuan; Huanchun Chen; Rui Zhou
Journal:  Clin Vaccine Immunol       Date:  2012-12-26

5.  Proteomic and immunoproteomic characterization of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae.

Authors:  Falk Fr Buettner; Sarah A Konze; Alexander Maas; Gerald F Gerlach
Journal:  Proteome Sci       Date:  2011-04-20       Impact factor: 2.480

6.  Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia.

Authors:  Lenka Sadilkova; Jiri Nepereny; Vladimir Vrzal; Peter Sebo; Radim Osicka
Journal:  Vet Res       Date:  2012-01-12       Impact factor: 3.683

7.  Complete Genome Sequence of Actinobacillus pleuropneumoniae Strain KL 16 (Serotype 1).

Authors:  Byung-Sun Park; Jemin Han; Dong-Ju Shin; Young-Ju Jeong; Nakhyung Lee
Journal:  Genome Announc       Date:  2017-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.